Table 2.

MG-ADL and QMG baseline mean values and differences of the means during a 26-week follow-up

	Baseline	Week 2	Week 10	Week 18	Week 26
MG-ADL§	9.37	−4	−5.29	−5.91	−5.58
(SD)	−3.28	−2.34	−2.86	−2.56	−2.96
95%CI	7.99–10.76	−4.98; −3.01	−6.50; −4.08	−7.00; −4.83	−6.83; −4.33
Median (IQR)	8.0 (6.0;12.0)	−3.0 (−5.75; −2.00)	−5.0 (−6.0; −4.0)	−6.0 (−7.5; −4.25)	−5.5 (−7.75; −3.25)
MG-ADL responders ^		17/24	19/24	17/22	17/21
(%)		−70.8	−79.2	−77.3	−81
QMG§	14.75	−4.5	−5.75	−6.21	−6.62
(SD)	−4.64	−2.99	−2.95	−3.23	−3.63
95%CI	12.79–16.71	−5.76; −3.23	−6.99; −4.50	−7.57; −4.84	−8.15; −5.09
Median (IQR)	14.5 (11.25–17.0)	−4.5 (−7.0; −2.25)	−5.5 (−8.0; −3.25)	−6.0 (−8.8; −4.0)	−7.0 (−8.0; −4.0)
QMG responders ^		Dec-24	15/24	14/22	14/21
(%)		−50	−62.5	−63.6	−66.7

Note: Values are expressed as mean ± SD and 95% CI

^§ Mean score at baseline and mean difference with respect to baseline during follow-up

° Mean dosage at baseline and mean dosage change during follow-up

MG-ADL Myasthenia Gravis Activity of Daily Living, QMG Quantitative Myasthenia Gravis, MGC Myasthenia Gravis Composite

^ MG-ADL responders: patients with reduction in MG-ADL score of at least 3 points from baseline; QMG responders: patients with reduction in QMG score of at least 5 points from baseline